Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
elanese now offers Zytel Resin, Hytrel TPC, Crastin PBT and Micromax Electronic Inks and Paste following its 2022 acquisition of the majority of the Mobility & Materials (M&M) business from DuPont
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Testing supporting allergy diagnosis now accessible to more people in more communities
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Subscribe To Our Newsletter & Stay Updated
